OncoMatch/Clinical Trials/NCT06663059
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
Is NCT06663059 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle and Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle for esophageal cancer.
Treatment: Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle · Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle — Observing the efficacy and safety of 2 cycles versus 4 cycles of Adebrelimab combined with chemotherapy as neoadjuvant treatment for patients with resectable locally advanced thoracic esophageal squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage T1B-4AN+M0, T2-4N0M0 (AJCC 8th edition)
Locally advanced thoracic esophageal cancer assessed by CT/MRI/EUS, with clinical staging T1b-4aN+M0 or T2-4N0M0 (T2N0 patients must have high-risk factors such as lymphovascular invasion [LVI], tumor size ≥3 cm, or poor differentiation) (according to AJCC 8th edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
No prior treatment for esophageal cancer, including radiotherapy, chemotherapy, or surgery
Cannot have received: chemotherapy
No prior treatment for esophageal cancer, including radiotherapy, chemotherapy, or surgery
Cannot have received: surgery
No prior treatment for esophageal cancer, including radiotherapy, chemotherapy, or surgery
Lab requirements
Blood counts
Neutrophil count ≥1.5 × 10^9/L; Platelet count ≥100 × 10^9/L; Hemoglobin ≥90 g/L
Kidney function
Serum creatinine ≤1.5 × ULN, or creatinine clearance ≥50 mL/min
Liver function
Total bilirubin ≤1.5 × ULN; ALT ≤2.5 × ULN, AST ≤2.5 × ULN
Normal major organ functions, including: Hematology (no use of blood components, growth factors, white blood cell stimulants, platelet stimulants, or anemia-correcting drugs within 14 days before the first use of the study drug): Neutrophil count ≥1.5 × 10^9/L; Platelet count ≥100 × 10^9/L; Hemoglobin ≥90 g/L; Biochemistry: Total bilirubin ≤1.5 × ULN; ALT ≤2.5 × ULN, AST ≤2.5 × ULN; Serum creatinine ≤1.5 × ULN, or creatinine clearance ≥50 mL/min; Coagulation: INR ≤1.5 × ULN; APTT ≤1.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify